Floatz logo

Venetoclax

Richter Syndrome

Northwestern UniversitySmall moleculePhase 2Active
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
81/ 100

Competitive context

35 Active assets in the Richter Syndrome cohort.

Asset / SponsorPhaseRating
Ibrutinib
City of Hope Medical Center
Phase 2BB
PREDNISONE TABLETS
SWOG Cancer Research Network
Phase 3BB
Cyclophosphamide
SWOG Cancer Research Network
Phase 3BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
SWOG Cancer Research Network
Phase 3BB
Pirtobrutinib
SWOG Cancer Research Network
Phase 3BB

View all 49 →

Same molecule, other indications

Venetoclax is also rated in:

Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveDormant
BBB
Indicative ·
72 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
BB
Indicative ·
70 / 100
View asset →
myeloid neoplasmDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →